Core Insights - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to address resistance to cancer immunotherapy [1] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 pm ET [1] Company Overview - TuHURA is developing technologies to overcome primary and acquired resistance to cancer immunotherapy, which are common reasons for the failure of these treatments [1] - The lead product, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors and is currently in a Phase 3 registration trial as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel Cell Carcinoma [1] Recent Developments - TuHURA acquired TBS-2025 through its merger with Kineta Inc. on June 30, 2025; TBS-2025 is a VISTA inhibiting monoclonal antibody moving into Phase 2 development for mutNPM1 r/r AML [1] - The company is also leveraging Delta Opioid Receptor technology to develop first-in-class bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells [1]